Two new simple and accurate solvent blends have been presented for the estimation of Valsartan (VAL) in bulk and its tablet dosage form. The developed analytical method was validated and established in ICH Q2 (R1). Valsartan exhibit 250 nm and 251 nm for Solvent A, Solvent B respectively and found was linear for a range of 1 µg/ml – 50 µg/ml. The goodness of fit study suggests good correlation coefficient R2 - 0.9998 and 0.9985 for proposed solvent blends. The validity of Beer’s law with intercept response < 2% calculated by the least square method indicating functional linearity between the concentration of analyte and the absorbance. The (LOD) and limit of quantification (LOQ) of Valsartan was within the quantifiable with % RSD < 2. The analytical method validation of proposed solvent blends was performed by carrying out precision and accuracy studies. The Accuracy percentage recovery on three different levels i.e. 50%, 100% and 150% was found to be within the acceptable limits with % RSD < 2. The proposed solvent blends were validated for specificity, precision, ruggedness, accuracy and robustness. Overall study suggest that the proposed solvent blends can be used for estimation of Valsartan in bulk and its tablet dosage form and can be applied for the everyday quality control analysis.

Effects of seven antihypertensives of Losartan Kalicum(LK), Atenolol(ATEN), Nifedipine(NF), Hydrochlorothiazide(HCTZ), Valsartan(VLA), Furosemide(FUR) and Captopril(CAP) have been investigated on the degradation behavior of AZ31 alloy in simulated body fluid (Hank’s solution). LK, NF and HCTZ with the concentrations of 0.5, 1.0 and 0.5 g/L can remarkably enhance the degradation resistance of AZ31 alloy by 63.1, 69.4 and 70.5%, respectively. The surface analysis reveals that the addition of LK, NF and HCTZ can reduce degradation rate by promoting the growth of hydroxyapatite, increasing the protection effect of corrosion film formed. The present results may enhance the corrosion resistance of Mg-based orthopedic implants.

Fabrication and optimization of valsartan-loaded transbilosomes for management of diabetes mellitus-accelerated stroke.

Sacubitril/valsartan (SAC/VAL) is a combination medication primarily used to treat heart failure with reduced ejection fraction (HFrEF). This randomized controlled trial (RCT) assessed the impacts of SAC/VAL compared with valsartan (VAL) on left ventricular (LV) remodeling, clinical outcomes, and cardiac function in patients with HFrEF. A single-blinded run-in phase and a double-blinded treatment phase were conducted at Imam Hospital (Ahvaz, Iran) among 106 patients (SAC/VAL group: n=54; VAL group=52). Patients were randomly assigned to receive a combination of SAC/VAL (up-titrated to the target dosage of 200 mg, twice daily) or VAL (up-titrated to 160 mg, twice daily) for a six-month of intervention. Patients' clinical, demographic, and echocardiographic data were collected before and after the intervention. After a six-month intervention, statistically significant mean differences were detected in various echocardiographic parameters (e.g., LV end-systolic volume, LV ejection fraction, and LV end-diastolic volume) within each group and between the two groups. Significant mean differences were noted in the six-minute walk test, serum levels of blood urea nitrogen, aspartate aminotransferase, sodium, creatinine, alanine aminotransferase, N-terminal pro-B-type natriuretic peptide, and scores of the Kansas City Cardiomyopathy questionnaire in post-intervention assessments within each group and between the two groups (P <0.05). There was a substantial within-group difference in the frequency of the New York Heart Association (NYHA) functional class from pre- to post-intervention (P <0.05). This study revealed that SAC/VAL exhibited superior efficacy compared to VAL. However, the follow-up period was relatively short, and the potential risks associated with the prolonged administration of this medication have not been thoroughly evaluated. This RCT indicated that the combination of SAC/VAL had better therapeutic effects than VAL on LV remodeling, clinical outcomes, and cardiac function in patients with ischemic HFrEF. These findings may help refine treatment priorities for patients with HFrEF and improve the quality of their care. IRCT20240117060713N1.

Valsartan (VAL) offers protection against atherosclerosis-associated diabetes mellitus (AADM) due to its antioxidant properties. However, VAL is hindered by poor bioavailability and effectiveness, which can be attributed to its low water solubility and significant first-pass metabolism. This research aimed to develop a nasal VAL–novasomes formulation (VNF) intended to enhance VAL’s efficacy, sustainability, bioavailability and targeting for AADM treatment. The Box–Behnken design was utilised for the development and optimisation of VNF formulations. The optimum VNF was subsequently evaluated in vivo using an experimental rat model of AADM. Compared to free VAL, the optimum VNF improved sustainability and bioavailability by 66.02% and 3.32-fold, respectively. The VNF group demonstrated significant reductions of 70.58%, 74.15%, 77.74% and 83.87% in glucose, triglycerides, cholesterol and LDL levels, respectively, compared to the AADM group. In contrast, HDL levels increased notably by 1.67-fold. Additionally, the VNF group accumulated 4.30 times more VAL in the heart than the free VAL group. Histopathological analysis confirmed the anti-atherosclerotic effect of the optimum VNF formulation. Importantly, the VNF group did not show any toxicity when compared to the negative control group. These findings support our hypothesis that the optimum VNF, administered nasally, could serve as a potential therapy for AADM.

Drug-coated balloon (DCB) therapy is a promising approach to treat peripheral artery disease (PAD), wherein lesion site preparation, balloon inflation, and the local delivery of anti-proliferative drugs such as paclitaxel (PTX) restores and retains lumen patency. Although largely successful in PAD applications, broader clinical deployment is in part limited by the occurrence of late lumen loss due to inward vessel remodeling at the treatment site, a maladaptive chronic response that has been clinically-observed to coincide with elevations in resident vascular smooth muscle cell (vSMC) tone. This study aims to explore a novel strategy to improve DCB efficacy via drug-based attenuation of vSMC tone at the treatment site. As a strategy to mitigate this post-DCB failure mode, we consider the local co-delivery of PTX and an additional drug that induces relaxation of vSMCs, specifically the clinically-approved anti-hypertensive drug valsartan (VAL). The potential benefit of drug-based regulation of vSMC tone is supported by recent theoretical studies that predict inward remodeling in the presence of hypertension and endothelial cell dysfunction, both common co-morbidities in PAD patients and established causes of elevated vSMC contractility. The specific selection of VAL as the anti-contractile payload constituent is motivated by its well-known pharmacokinetic and safety profiles, and the notion that current clinical use and familiarity could promote rapid translation in the context of DCBs. Our obtained results quantify the potency of VAL to induce local vSMC relaxation in arterial tissue, demonstrate the feasibility of PTX and VAL co-delivery using the canonical excipient urea for balloon coating formation, and elucidate key structure-function relations to facilitate efficient drug delivery with these novel coatings. Our study supports the continued evaluation of VAL for inclusion in DCB formulations due to its potential to redirect post-treatment arterial remodeling. Future in-vivo studies which examine the co-delivery of PTX and VAL in the context of DCBs are needed to establish both the safety and efficacy of this novel approach.

BackgroundUncontrolled diabetes results in diabetic kidney disease (DKD), impacting approximately 40% of individuals with diabetes. Early indicators include podocyte damage and proteinuria, which are influenced by oxidative stress and dysregulation of the Nrf2/HO-1 pathway.ObjectiveTo examine the potential effect of Sacubitril/valsartan (LCZ696) on the oxidative stress of podocytes induced by hyperglycemia via the signaling pathway.MethodsPodocytes were categorized into four groups: the first group was exposed to a normal glucose level 5.5 mmol/L, the second group to a high glucose at 40 mmol/L, the third group to a high glucose with LCZ696 at a concentration of 10 µM and the fourth group to a high glucose with Valsartan (VAL) at a concentration of 10 µM. Cell viability was evaluated using the CCK-8 assay. The rate of apoptosis in podocytes was determined through flow cytometry with Annexin V-FITC and PI staining. Oxidative stress parameters were assessed using ROS detection kits. To explore the role of Nrf2 signaling, its expression in podocytes was silenced via siRNA transfection, enabling the evaluation of LCZ696’s effects on oxidative stress and apoptosis in the absence of Nrf2 signaling. The expression levels of HO-1 and Nrf2 were analyzed through Western blotting and real-time polymerase chain reaction (rtPCR).Results and discussionThe Cell viability study results suggested that a 10 µM concentration of LCZ696 showed better effects. LCZ696 at 10 µM significantly enhanced cell viability and reduced apoptosis in podocytes exposed to high glucose levels. Apoptotic markers showed a notable decrease in the HG + LCZ696 group compared to the HG group, highlighting LCZ696’s superior efficacy over VAL in preventing glucose-induced cell death. The HG group showed significantly higher levels of ROS and MDA compared to the NG group, whereas the SOD levels were considerably lower. ROS levels in the HG + LCZ696 and HG + VAL groups were considerably lower than those in the HG group. Additionally, oxidative stress markers, such as ROS and MDA, were significantly reduced, while SOD levels were notably increased in the LCZ696 and VAL groups compared to the HG group. The relative protein mRNA expression levels of Nrf2 and HO-1 in the HG + LCZ696 group were significantly higher (P < 0.001) compared to the HG group. Compared to the NG group, the relative expression levels of the Nrf2 and HO-1 were lower in the HG group (P < 0.01) and significantly higher in the HG + LCZ696 group than in the NG group (P < 0.05). Moreover, LCZ696 upregulated Nrf2 and HO-1 protein and gene expression levels, mitigating oxidative stress. siRNA-mediated knockdown of Nrf2 further confirmed that LCZ696’s protective effects were Nrf2-dependent, as Nrf2 suppression eliminated LCZ696’s antioxidative and anti-apoptotic benefits, underscoring Nrf2’s role in LCZ696’s mechanism.ConclusionsLCZ696 can inhibit oxidative stress and improve elevated glucose-induced apoptosis in podocytes via the Nrf2/HO-1 signaling pathway.Graphical

ABSTRACT Pharmaceutical pollutants like Atenolol (ATN), Rosuvastatin (RSV), and Valsartan (VAL) pollute water, harm aquatic life, and resist standard treatment. To address this challenge, our study developed low-cost, eco-friendly activated carbon (AC) from sumac seeds, using Phosphoric acid (H₃PO₄) as the activating. The resulting sumac-based AC (AC(S)) boasts an impressive surface area of 730 m2/g and demonstrates excellent adsorption (ADS) performance for these pharmaceutical contaminants in aqueous solutions. The adsorbent doses used were 1.5 g/L for ATN and VAL and 0.5 g/L for RSV at the original pH and 30 °C temperature, achieving up to 96% for each molecule individually. ADS contact time of VAL adsorbed rapidly 30 minutes, while ATN and RSV required 2 hours. The kinetic and isotherm studies were more fitted to the pseudo-second-order model (2nd order) R2 (0.9999, 0.9999 and 0.9998) and Langmuir model R2 (0.9997, 0.9990 and 0.9997), with maximum capacity 99.7 mg/g, 107.9 mg/g, and 241 mg/g for ATN, RSV, and VAL respectively. Sulfuric acid (H₂SO₄) served as an eluent for the regeneration of the adsorbent. AC(S) regeneration and reuse for the three pharmaceutical molecules removal were tested for 10 cycles.

Pharmaceutical residues in aquatic environments are emerging contaminants of concern due to their potential sublethal and chronic impacts on aquatic organisms. This study aimed to evaluate the subacute toxicological effects of three widely used pharmaceuticals-gabapentin (GAB), valsartan (VAL), and codeine (COD)-on male African catfish (Clarias gariepinus). Fish were randomly assigned to four groups: a control group and three treatment groups exposed for 15days to environmentally relevant concentrations of GAB (79.86µg/L), VAL (28.22µg/L), and COD (5.27µg/L), respectively. Hematological indices including hematocrit (Ht), hemoglobin (Hb), erythrocyte (RBC), leukocyte (WBC), and lymphocyte counts were significantly reduced in all exposed groups relative to controls. Biochemical analysis revealed elevated levels of AST, ALT, glucose, total protein, total cholesterol, uric acid, and creatinine in the GAB group, while VAL exposure led to increased total protein and creatinine levels and decreased alkaline phosphatase (ALP) activity. Antioxidant assessments showed a significant reduction in superoxide dismutase (SOD) following VAL exposure, with total antioxidant capacity (TAC) and catalase (CAT) activities significantly reduced across all treated groups. Histopathological and histochemical examinations of the liver revealed tissue degeneration, fibrosis, and glycogen depletion, with the most severe alterations observed in the VAL group. These findings highlight the potential adverse effects of chronic pharmaceutical exposure on fish physiology and liver function, with VAL demonstrating the most pronounced impact among the tested compounds.

Synthesis and evaluation of valsartan co-crystals for enhanced solubility and anti-hypertensive activity.

At present, one of the main priorities for analysts is creating more sustainable and environmentally friendly methods for pharmaceutical analysis. In this context, three innovative spectrophotometric techniques, using tri-colored (green, blue, and white), were optimized and developed to simultaneously assess two antihypertensive drugs, Nebivolol hydrochloride (NEB) and Valsartan (VAL), in the presence of synthetic precursor impurity of Valsartan (Valsartan Desvaleryl, VAL-D), which is the main acidic degradation product. The methods employed, including the double divisor-ratio spectra derivative spectrophotometric method, the dual-wavelength in ratio spectrum method, and the H-point derivative ratio method, displayed a good linear range of 2.5–70 µg/mL, 10–50 µg/mL, and 10–70 µg/mL for NEB, VAL, and VAL-D, respectively. Assessment of greenness was implemented to the established methods using the analytical Eco-Scale scoring, analytical greenness metric (AGREE), and the green analytical process index (GAPI). The concepts of blueness assessment using the recently introduced Blue Applicability Grade Index (BAGI tool) and whiteness assessment using the Red Green Blue 12 (RGB 12 tool) were also applied. The proposed methods were validated as per ICH guidelines and verified to be accurate. Statistical analysis was performed to ensure the validity of methods concerning published methods.

Background: Hypertension (HTN) is recognized as a major risk factor for cardiovascular disease, chronic kidney disease, and peripheral artery disease. Valsartan (VAL), an angiotensin receptor blocker drug for hypertension, has been limited due to its poor solubility and poor absorption from the GIT, which leads to low oral bioavailability. Objectives/Method: In the present research, firstly, VAL-loaded nanoliposomes were formulated and optimized using the Box–Behnken design (BBD). Optimized VAL-nanoliposomes were physically characterized and their fate was examined by scanning and transmission microscopy, DSC, FTIR, XRD, and ex vivo studies using rat skin. In vitro studies using human keratinocyte (HaCaT) cells showed a decrease in cell viability as the liposome concentration increased. Secondly, the formulation of VAL-loaded nanoliposomes was integrated into dissolvable microneedles (DMNs) to deliver the VAL transdermally, crossing the skin barrier for better systemic delivery. Results: The optimized nanoliposomes showed a vesicle size of 150.23 (0.47) nm, a ZP of −23.37 (0.50) mV, and an EE% of 94.72 (0.44)%. The DMNs were fabricated using a ratio of biodegradable polymers, sodium alginate (SA), and hydroxypropyl methylcellulose (HPMC). The resulting VAL-LP-DMNs exhibited sharp pyramidal microneedles, adequate mechanical properties, effective skin insertion capability, and rapid dissolution of the microneedles in rat skin. In the ex vivo analysis, the transdermal flux of VAL was significantly (5.36 (0.39) μg/cm2/h) improved by VAL-LP-DMNs. The enhancement ratio of the VAL-LP-DMNs was 1.85. In conclusion, liposomes combined with DMNs have shown high potential and bright prospects as carriers for the transdermal delivery of VAL. Conclusions: These DMNs can be explored in studies focused on in vivo evaluations to confirm their safety, pharmacokinetics profile, and pharmacodynamic efficacy.

Spectrophotometric method based on Continuous wavelet transform and ratio substraction methods for the rapid simultaneous quantification of Valsartan, Amlodipine, and hydrochlorothiazide in cardiovascular tablet formulation.

This study aims to develop and validate a Ultra violet spectroscopic analytical method for accurately measuring Olmesartan Medoxomil (OLM), Telmisartan (TEL), and Valsartan (VAL), three common antihypertensive drugs. These medications block angiotensin II at the AT1 receptor, reducing blood pressure through vasodilation and decreased water retention. UV spectrophotometry offers a simple and cost-effective approach for drug quantification. The objective is to establish specific wavelengths for each drug and evaluate derivative and AUC techniques for precise measurement. A diluent of 0.1N sodium hydroxide and distilled water (3:7) was used, yielding wavelengths of 248 nm for OLM, 295 nm for TEL, and 250 nm for VAL in zero-order analysis. First-order derivative peaks were identified at 264 nm, 284 nm, and 267 nm, while second-order derivatives showed 252 nm, 241 nm, and 239 nm for OLM, TEL, and VAL, respectively. AUC analysis further refined ranges for each compound. The method was validated for accuracy, precision, sensitivity, and detection limits using this solvent system. Results demonstrated that the UV spectrophotometric method was effective for the precise quantification of OLM, TEL, and VAL. The common solvent system ensured efficiency in routine quality control. In pharmaceutical settings, this approach offers a dependable, rapid, and economical technique for monitoring these drugs.

Alterations of valsartan pharmacokinetics in a rodent model of metabolic dysfunction-associated steatohepatitis.

Introduction: A new method for valsartan (VST) estimation in pharmaceutical dosage samples by spectrophotometry was developed. Methods: The method was based on the formation of coloured dye by the diazotization reaction of 3-amino-2-naphthol with sodium nitrite in an acidic medium to form diazonium compounds, which were then coupled with VST in a basic medium. Results: The drug sample showed linearity in the range 4.6 - 24.2 μgmL-1, and the λmax was found at 432nm. Sandell’s sensitivity (9.950×10-3), Molar absorbtivity (Ɛ= 4.377×104), regression equa-tion (y= 0.0775x + 0.0041), correlation coefficient (r2= 0.968), detection limit (DL= 0.668) and quantitation limit (QL= 2.024) were evaluated. Conclusion: The percentage recovery of the drug samples was found to be 100%. This method successfully determined VST in Pharmaceutical dosage samples.

Ischemia-reperfusion injury (IRI) is a common pathogenic situation that arises throughout all liver surgeries, including liver transplants. We aimed to compare the preventive effects of valsartan (VST) against valsartan + sacubitril (LCZ696) on hepatic injury caused by IRI. A total of thirty-six male Westar albino rats were split into six groups randomly: sham, IRI, VST + IRI, LCZ696 + IRI, VST, and LCZ696. The medicines were given orally for 10days in a row. Hepatic tissues and blood were examined through histopathological imaging and immunohistochemical detection of hepatic SMAD-4 protein expression plus serum aminotransferase (ALT, AST) and gamma-glutamyl transferase (GGT) levels. Angiotensin II, aldosterone, and plasma renin activity were evaluated in rat serum. Liver tissue homogenate was utilized to assess reduced glutathione (GSH), myeloperoxidase (MPO), malondialdehyde (MDA), and total nitric oxide (NOx) levels. Pro-inflammatory indicators, tumor necrosis factor-alpha (TNF-α), and interleukin-1β (IL-1β), moreover with apoptosis indicators, BCL2-associated X protein (Bax), B-cell lymphoma 2 (Bcl-2), and galactine-9 (GAL9) proteins plus caspase-3, were measured in hepatic tissue homogenate. Hepatic endothelin-1 and neprilysin activity were evaluated. Western blot was done for c-Jun N-terminal kinase (JNK-7) plus nuclear factor-kappa B (NF-κβ) expressions. The study revealed that VST and LCZ696 pretreatment showed significant restoration of liver injury, correction of oxidative profile, and inhibition in the angiotensin II receptor-neprilysin pathway. Inflammatory mediators and apoptosis were significantly inhibited. The expression of SMAD-4, JNK-7, and NF-κβ proteins was notably diminished. The improvement in hepatic architecture supports these histopathological results. In conclusion, LCZ696 possesses a potentially significant protective effect against liver IRI superior to VST alone.

Valsartan (VST) is an angiotensin II receptor antagonist with low oral bioavailability. The present study developed a solid self-nanoemulsifying drug delivery system (S-SNEDDS) to enhance the oral absorption and bioavailability of VST. VST-loaded liquid SNEDDS (VST@L-SNEDDS) was prepared by investigating the solubility of VST and constructing the pseudo-ternary phase diagrams. The formulation of VST@S-SNEDDS was obtained by adsorbing VST@L-SNEDDS onto a solid carrier. In vitro studies including drug dissolution, stability, cytotoxicity, and Caco-2 uptake of VST@S-SNEDDS were assessed. An in vivo pharmacokinetic study of VST@S-SNEDDS was employed to evaluate the oral bioavailability of VST. VST@L-SNEDDS, with an average particle size of 19.90 nm and zeta potential of -20.57 mV, consisted of 12.37% VST (drug loading), 21.91% ethyl oleate, 45.50% RH 40, and 20.22% Transcutol HP. VST@S-SNEDDS was prepared using Neusilin® UFL2 as a solid adsorbent, which contained VST@L-SNEDDS at 2.28 ± 0.15 g/g. The in vitro release study demonstrated that VST@S-SNEDDS exhibited rapid release characteristic without affecting by the pH of the media, and dissolution rates exceeded 90% within 60 min in different media. The long-term stability of VST@S-SNEDDS was better than that of VST@L-SNEDDS. These two formulations increased the Caco-2 uptake significantly. The area under the drug concentration-time curve (AUC0-24h) and peak drug concentration in plasma (Cmax) of VST@S-SNEDDS increased by 2.28-fold and 4.86-fold compared to raw VST, respectively. The proposed VST@S-SNEDDS represents a novel approach to enhance the oral absorption and bioavailability of VST, providing a promising avenue for hypertension treatment.

Valsartan (VAL) and Polythiazide (PTZ) combination is a crucial therapeutic advancement in the management of hypertension, necessitating precise analytical methods for ensuring quality. A specific, fast RP-HPLCmethodwasdeveloped and validated for co-estimation of VAL and PTZ on a Kromasil C-8 column (150×4.6 mm, 5µm). Maximum separation was attained with gradient elution by the use of ammonium dihydrogen phosphate buffer (pH3.0) and methanol: acetonitrile (50:50) as mobile phases at the flow rates of 1.2 mL/min and detection wavelength265 nm. The method had an excellent linearity (R² &gt; 0.999) in ranges 8-12 µg/mL for PTZ and 32-48 µg/mLfor VAL. Method validation revealed good precision (RSD ≤ 0.39%), accuracy (recovery 98.40-100.25%), androbustness. LOD and LOQ were 0.15 µg/mL and 0.45 µg/mL for PTZ, and 0.25 µg/mL and 0.75 µg/mLfor VAL, respectively. The short analysis time (10 min) of the method, easy mobile phase preparation, and extensivevalidation of the method make it ideal for routine quality control analysis of this valuable antihypertensivecombination, with the advantage of quicker analysis and better sensitivity than the prevailing methods.

Hypertension is the most common entity globally, marked by high prevalence and heterogeneous pathophysiology. Oxidative stress is a crucial area of investigation among potential etiologies. We examined the hypothesis that blocking the angiotensin type 1 (AT1) receptor with valsartan (VST) in self-nanoemulsifying delivery systems (SNEDS) and loads in liquisolid tablets (LST-1) or valsartan and hydrochlorothiazide (VST/HCTZ) in SNEDS and loads in liquisolid tablets (LST-2) in comparison with non-SNEDS liquisolid tablets (DCT-3 and DCT-4) would lead to an improvement in hypertension management. The present study aims to explore the molecular mechanisms underlying their effect in N(G)-nitro-L-arginine methyl ester (L-NAME)-induced hypertensive rats. Male Sprague–Dawley rats were given L-NAME (40 mg/kg/day) orally for three weeks to inhibit the endogenous synthesis of nitric oxide (NO). Concurrent treatment with VST or VST/HCTZ liquisolid tablets (20 mg/kg/day for three weeks) resulted in lowering blood pressure (BP), reversing the L-NAME-induced serum NO suppression, enhancing lipid profile, and improving oxidative status. The antioxidant defense of paraoxonase was significantly increased in the LST-1- and LST-2-treated rats compared to the L-NAME-treated rats by 135% and 90%, respectively. Furthermore, SNEDS-loaded VST or SNEDS-loaded VST/HCTZ liquisolid tablets significantly lowered the elevated level of AT1 (P < 0.05), showed a marked Nrf2 expression (P < 0.01) and overexpressed PPARγ (P < 0.05), and suppressed iNOS expression (P < 0.0001). These results highlight the remarkable benefits of the novel formula, “SNEDS-loaded VST and SNEDS-loaded VST/HCTZ,” as an alternative therapy in treating hypertension and its complications.Graphical abstractSchematic diagram showing the mechanism of SNEDS-loaded VST and SNEDS-loaded VST/HCTZ as potential treatment strategies for hypertension. This mechanism includes the reduction of iNOS expression, antioxidant activity, and AT1R normalization action through activation of the Nrf2/PPARγ signaling cascade.